Business Update

Biopharmaceutical company to expand manufacturing facility for vaccine products

Published in Vaccine Weekly, August 11th, 2004

Nabi Biopharmaceuticals (NABI) announced that in line with its plans to prepare for the commercialization of its vaccine product portfolio, it has initiated construction of a state-of-the-art bulk vaccine manufacturing facility within available space in the company's licensed biopharmaceutical manufacturing facility located in Boca Raton, Florida.

The production capacity in this facility will initially be used to support the commercialization of StaphVAX (Staphylococcus aureus Polysaccharide Conjugate Vaccine), the company's lead product candidate initially targeted to prevent staph infections in end-stage renal (kidney) disease (ESRD) patients.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Vaccine Weekly

Source: Vaccine Weekly (2004-08-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry